Voyager Therapeutics
VYGR
113 hedge funds and large institutions have $377M invested in Voyager Therapeutics in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 35 increasing their positions, 40 reducing their positions, and 20 closing their positions.
11,983% more call options, than puts
Call options by funds: $1.45M | Put options by funds: $12K
36% more capital invested
Capital invested by funds: $277M → $377M (+$99.7M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.28% less ownership
Funds ownership: 81.5% → 80.23% (-1.3%)
7% less funds holding
Funds holding: 121 → 113 (-8)
13% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 40
40% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$4.75M |
| 2 |
Bank of New York Mellon
New York
|
+$2.61M |
| 3 |
BlackRock
New York
|
+$2.58M |
| 4 |
Axa
Paris,
France
|
+$2.11M |
| 5 |
ClearBridge Investments
New York
|
+$1.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$4.01M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.53M |
| 3 |
Renaissance Technologies
New York
|
-$2.29M |
| 4 |
Millennium Management
New York
|
-$2.03M |
| 5 |
AC
Armistice Capital
New York
|
-$1.84M |
VYGR Hedge Fund Activity: Q2 2020 in Review
113 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q2 2020, worth a combined $377M — up 36% from $277M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of VYGR and 12 opened new positions — a net loss of 8 holders — while 40 trimmed existing stakes and 35 added.
The largest buyer was Citadel Advisors, adding an estimated $4.75M. The largest seller was Casdin Capital, cutting an estimated $4.01M.
- 113 institutional investors held Voyager Therapeutics (VYGR) as of Q2 2020, down from 121 in Q1 2020.
- Funds reported $377M of Voyager Therapeutics stock for Q2 2020, up 36% quarter-over-quarter.
- 12 funds opened new Voyager Therapeutics positions in Q2 2020 and 20 closed out, a net change of -8 holders.
- The largest Voyager Therapeutics buyer in Q2 2020 was Citadel Advisors, an estimated $4.75M added.
- The largest Voyager Therapeutics seller in Q2 2020 was Casdin Capital, an estimated $4.01M sold.
Based on aggregated 13F filings for Q2 2020.